Andy Fuller Appointed VP of Market Access at AESAR

AESARA, a leading digital-forward Value & Access agency, is pleased to announce the appointment of Andy Fuller as Vice President of US Market Access within its Strategic Partnerships team. With over 27 years of experience in the pharmaceutical industry, Andy Fuller brings extensive expertise in developing and executing go-to-market and payer engagement strategies across highly competitive markets.

Ruslan Horblyuk, Chief Strategic Consulting Officer at AESARA, commented, “Andy’s impressive track record in Sales, Marketing, and Market Access leadership roles makes him an ideal addition to our Strategic Partnerships team. His expertise aligns perfectly with our focus on expanding AESARA’s Value and Access portfolio and capabilities. We’re excited to work alongside Andy and benefit from his wealth of experience.”

Fuller’s appointment comes at a pivotal time for AESARA as the company continues to deliver innovative and trusted solutions that drive transformative market access for its clients.

“I’m thrilled to join AESARA and contribute to its mission of powering transformative market access,” said Andy Fuller. “The pharmaceutical landscape is rapidly evolving, and I look forward to leveraging my experience to help our clients navigate these changes and maximize their market impact.”

Sissi Pham, CEO of AESARA, added, “We are delighted to welcome Andy Fuller to our Value & Access team. His extensive industry knowledge and strategic insights will be invaluable as we continue to elevate our clients’ market access influence within their organizations and the decisionmakers within the US healthcare ecosystem. With Fuller’s addition, AESARA reinforces its commitment to providing cutting-edge market access solutions and further solidifies its position as a leader in the Value & Access space.”

SourceAESARA

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version